Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 8/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | RARA | P10276 | 7/20 | 0.35 |
| ▸ | RARB | P10826 | 7/20 | 0.35 |
| ▸ | RARG | P13631 | 6/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564854 | 0.82 | GSK3B (0.42) | CYP3A4GSK3BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL4496412 | 0.81 | GSK3B (0.41) | GSK3BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL4493700 | 0.80 | RARB (0.41) | CYP26A1CYP3A4CYP26B1GSK3BRXRA | |
| SCHEMBL4000987 | 0.78 | GSK3B (0.38) | CYP26A1CYP3A4CYP26B1GSK3BRXRA | |
| SCHEMBL4564852 | 0.73 | GSK3B (0.40) | GSK3BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4587769 | 0.69 | GSK3B (0.40) | GSK3B | |
| SCHEMBL4483107 | 0.68 | GSK3B (0.38) | GSK3BPIK3CDPIK3CB | |
| SCHEMBL4489695 | 0.68 | GSK3B (0.38) | GSK3BPIK3CDPIK3CB | |
| SCHEMBL4483112 | 0.68 | GSK3B (0.38) | GSK3BPIK3CDPIK3CB | |
| SCHEMBL4473700 | 0.67 | GSK3B (0.55) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | claimed |
| US-7067521-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7pyridinyl-imidazo[1,2-alpha]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-06-27 | — | — | US | claimed |
| EP-1315730-B1 | 1-(ALKYL), 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO(1,2-A)PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-30 | — | — | EP | claimed |
| US-7608624-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives | SANOFI-AVENTIS (FR) | 2009-10-27 | — | — | US | disclosed |
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | disclosed |
| EP-1315730-B1 | 1-(ALKYL), 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO(1,2-A)PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | PSEN1, PSEN2, SNCA | CYP26A1 799/4885CYP3A4 2886/4885CYP26B1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.